tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2016-4-21-29tumors-268Research ArticleФУНДАМЕНТАЛЬНАЯ ОНКОЛОГИЯ И ЭКСПЕРИМЕНТАЛЬНАЯ МЕДИЦИНАFUNDAMENTAL ONCOLOGY AND EXPERIMENTAL MEDICINEПЕРСПЕКТИВЫ ИСПОЛЬЗОВАНИЯ МЕЛАТОНИНА В КЛИНИЧЕСКОЙ ОНКОЛОГИИPERSPECTIVES OF MELATONIN USE IN CLINICAL ONCOLOGYCемиглазоваТ. Ю.SemiglazovaT. U.

Семиглазова  Татьяна Юрьевна – доктор медицинских наук, заведующая отделом инновационных методов терапевтической онкологии и реабилитации, Санкт-Петербург 

Semiglazova  Tatiana Yuryevna – MD, PhD, DSc, professor, Head of Department, Leading Researcher at the Department of Innovative Methods of Therapeutic Oncology and Rehabilitation

tsemiglazova@mail.ruОсиповМ. А.OsipovM. A.

Осипов Михаил Анатольевич – лаборант–исследователь отдела инновационных методов терапевтической онкологии и реабилитации, Санкт-Петербург

Osipov Mikhail Anatolievich – assistant-researcher at the Department of Innovative Methods of Therapeutic Oncology and Rehabilitation

ocipovmixail@mail.ruНовикА. В.NovikA. V.

Новик Алексей Викторович – кандидат медицинских наук, врач–онколог, Санкт-Петербург

Novik Aleksej Viktorovich – MD, PhD, medical oncologist

anovik@list.ruКлименкоВ. В.KlimenkoV. V.

Klimenko Veronika Viktorovna – MD, PhD, medical oncologist

veronika30081987@mail.ruАнисимовВ. Н.AnisimovV. N.

Анисимов Владимир Николаевич – член–корр. РАН, доктор медицинских наук, профессор, руководитель отдела канцерогенеза и онкогеронтологии, Санкт-Петербург 

Anisimov Vladimir Nikolaevich  – MD, PhD, DSc, professor, corresponding member of the Academy of Sciences of Russia, Head of Department of Carcinogenesis  and Oncogerontology

aging@mail.ruНаучно-исследовательский институт онкологии имени Н. Н. ПетроваРоссияScientific Research Institute of Oncology na N. N. PetrovRussian Federation201616112016042129Copyright © Cемиглазова Т.Ю., Осипов М.А., Новик А.В., Клименко В.В., Анисимов В.Н., 20162016Cемиглазова Т.Ю., Осипов М.А., Новик А.В., Клименко В.В., Анисимов В.Н.Semiglazova T.U., Osipov M.A., Novik A.V., Klimenko V.V., Anisimov V.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/268

В 21-м веке достигнуты значительные успехи в лекарственном лечении злокачественных опухолей. Применение новых препаратов позволяет увеличить время до прогрессирования заболевания, продолжительность жизни больных, улучшить ее качество. В последнее время активно изучается противоопухолевая активность гормона эпифиза мелатонина. Этой теме посвящены многочисленные опыты invitro/invivo, в которых показана способность мелатонина тормозить злокачественный рост и потенцировать действие цитостатиков. В данном обзоре освещены данные о использовании мелатонина при лечении пациентов с солидными опухолями. Мелатонин использовался  как в монотерапии, так и в комбинации с химиотерапией и иммунотерапией. Согласно результатам этих исследований применение мелатонина приводит к увеличению объективных ответов и общей выживаемости пациентов и к снижению частоты побочных эффектов химиотерапии. Однако этот гормон эпифиза до сих пор рутинно не используется в клинической онкологии и его активность следует изучать в дальнейшем в рамках рандомизированных клинических исследований.

Nowadays great successes have been reached in chemotherapy treatment of cancer. New medications let increase time to progression,  overall survival and to improve a quality of life. Recently, antitumor activity of melatonin is actively investigated. Many in vitro/in vivo studies are devoted to this topic. In these trials was shown ability of melatonin to inhibit tumor growth and to potentiate the cytotoxic effects of chemotherapy. This review describes the use of melatonin in the treatment of patients with solid tumors. Melatonin has been used in both monotherapy and in combination with chemotherapy and immunotherapy. According to these studies, the use of melatonin increases the objective response and overall survival of patients and reduce the incidence of side effects of chemotherapy. However, this epiphyseal hormone does not routinely used in clinical oncology and will be must to investigate it in more clinical trials. 

мелатонинхимиотерапияклинические исследованияmelatoninchemotherapyclinical trialsReferencesParkin M., Fern ndez L. Use of Statistics to Assess the Global Burden of Breast Cancer // Breast J.– 2006.– Vol.12.– S.70–80.Parkin M., Fern ndez L. Use of Statistics to Assess the Global Burden of Breast Cancer // Breast J.– 2006.– Vol.12.– S.70–80.Lerner А., Case J., Takahashi Y., Lee T. et al. Isolation of melatonin, the pineal gland factor that lightens melanocytes // J. Am Chem Soc.– 1958.– Vol.80 (10).– P. 2587–2587.Lerner А., Case J., Takahashi Y., Lee T. et al. Isolation of melatonin, the pineal gland factor that lightens melanocytes // J. Am Chem Soc.– 1958.– Vol.80 (10).– P. 2587–2587.Saper C., Scammel T., Lu J. Hypothalamic regulation of sleep and circadian rhythms // Nature.– 2005.– Vol. 437.– P. 1257–1263.Saper C., Scammel T., Lu J. Hypothalamic regulation of sleep and circadian rhythms // Nature.– 2005.– Vol. 437.– P. 1257–1263.Анисимов В. Н. Физиологические функции эпифиза//Рос. Физиол. ж. имени И. М. Сеченова – 1997.– Т. 83.– № 8.– С. 1–13. Anisimov V. N., The physiological function of the pineal gland // Rus.Phys.J.–1997.– Vol.83(8).– P. 1–13.Анисимов В. Н. Физиологические функции эпифиза//Рос. Физиол. ж. имени И. М. Сеченова – 1997.– Т. 83.– № 8.– С. 1–13. Anisimov V. N., The physiological function of the pineal gland // Rus.Phys.J.–1997.– Vol.83(8).– P. 1–13.Reiter R. J. Interactions of the pineal hormone melatonin with oxygen – centered free radicals: a brief review // Braz J Med Res.– 1993.– Vol. 25.– P. 1141–1145.Reiter R. J. Interactions of the pineal hormone melatonin with oxygen – centered free radicals: a brief review // Braz J Med Res.– 1993.– Vol. 25.– P. 1141–1145.Anisimov V. N. The solar clock of aging // Acta Geront.–1994.– Vol.45.– P. 10–18.Anisimov V. N. The solar clock of aging // Acta Geront.–1994.– Vol.45.– P. 10–18.Carrillo-Vico A., Lardone P., Varez – Sanchezn et al. Melatonin: buffering the immune system // Int. J. Mol. Sci.– 2013.– Vol.14.– P. 8638–8683.Carrillo-Vico A., Lardone P., Varez – Sanchezn et al. Melatonin: buffering the immune system // Int. J. Mol. Sci.– 2013.– Vol.14.– P. 8638–8683.Haldar C., Rai S., Singh R. Melatonin blocks dexamethasoneinduced immunosuppression in a seasonally breeding rodent indian palm squirrel, funambulus pennant // Steroids.–2004.– Vol.69.– P. 367–377.Haldar C., Rai S., Singh R. Melatonin blocks dexamethasoneinduced immunosuppression in a seasonally breeding rodent indian palm squirrel, funambulus pennant // Steroids.–2004.– Vol.69.– P. 367–377.Dubocovich M., Delagrange P., Krause et al. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupledmelatonin receptors // Pharmacol Rev.– 2010.– 62.– P. 343–380.Dubocovich M., Delagrange P., Krause et al. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupledmelatonin receptors // Pharmacol Rev.– 2010.– 62.– P. 343–380.Wang J., Xiao X., Zhang Y. Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells // J Pineal Res.– 2012.– Vol.53(1).– P. 77–90.Wang J., Xiao X., Zhang Y. Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells // J Pineal Res.– 2012.– Vol.53(1).– P. 77–90.Jung-Hynes B., Schmit T., Reagan-Shaw S. Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model // J Pineal Res.– 2011.– Vol.50(2).– P. 140–9.Jung-Hynes B., Schmit T., Reagan-Shaw S. Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model // J Pineal Res.– 2011.– Vol.50(2).– P. 140–9.Zisapel N., Bubis M. Inhibition by melatonin of protein secretion and growth of melanoma cells in culture // Adv. Pineal Res.– 1994.– Vol.7.– P. 259–268.Zisapel N., Bubis M. Inhibition by melatonin of protein secretion and growth of melanoma cells in culture // Adv. Pineal Res.– 1994.– Vol.7.– P. 259–268.Anisimov V., Zabezhinski M., Popovich I. et al. Inhibitory effect of melatonin on 7,12-dimethylbenz[a]anthracene induced carcinogenesis of the uterine cervix and vagina in mice and mutagenesis in vitro // Cancer Lett.– 2000.– Vol.156.– P. 199–205.Anisimov V., Zabezhinski M., Popovich I. et al. Inhibitory effect of melatonin on 7,12-dimethylbenz[a]anthracene induced carcinogenesis of the uterine cervix and vagina in mice and mutagenesis in vitro // Cancer Lett.– 2000.– Vol.156.– P. 199–205.Blask D. Melatonin Inhibition of Cancer Growth in Vivo Involves Suppression of Tumor Fatty Acid Metabolism via Melatonin Receptor-mediated Signal Transduction Events // Cancer Res.– 1999.– Vol.59.– P. 4693–4701.Blask D. Melatonin Inhibition of Cancer Growth in Vivo Involves Suppression of Tumor Fatty Acid Metabolism via Melatonin Receptor-mediated Signal Transduction Events // Cancer Res.– 1999.– Vol.59.– P. 4693–4701.Попович И. Г., Панченко А. В., Тындык М. Л., Аникин И. В., Забежинский М. А., Семиглазова Т. Ю., Осипов М. А., Анисимов В. Н. Влияние противоопухолевых препаратов и их комбинаций с мелатонином на рост перевиваемой опухоли молочной железы с инкорпорированным геном HER2/ neu у самок мышей FBV // Материалы VII съезда онкологов и радиологов СНГ и Евразии.– Казань, 2014.– С. 116. Popovich I. G., Panchenko A. V., Tyndyk M. L., Anikin I. V., Zabezhinski M. A., Semiglazova T. U., Osipov M. A., Anisimov V. N. Influence of cytotoxic drugs with melatonin on growth of transplantable breast tumor incorporated HER2 neu gene in female FBV mice // Materials of the VII congress of oncologists and radiologists of CIS and Eurasia.– Kazan,2014.– P. 116.Попович И. Г., Панченко А. В., Тындык М. Л., Аникин И. В., Забежинский М. А., Семиглазова Т. Ю., Осипов М. А., Анисимов В. Н. Влияние противоопухолевых препаратов и их комбинаций с мелатонином на рост перевиваемой опухоли молочной железы с инкорпорированным геном HER2/ neu у самок мышей FBV // Материалы VII съезда онкологов и радиологов СНГ и Евразии.– Казань, 2014.– С. 116. Popovich I. G., Panchenko A. V., Tyndyk M. L., Anikin I. V., Zabezhinski M. A., Semiglazova T. U., Osipov M. A., Anisimov V. N. Influence of cytotoxic drugs with melatonin on growth of transplantable breast tumor incorporated HER2 neu gene in female FBV mice // Materials of the VII congress of oncologists and radiologists of CIS and Eurasia.– Kazan,2014.– P. 116.Осипов М. А., Попович И. Г., Тындык М. Л., Панченко П. А., Забежинский М. А., Семиглазова Т. Ю., Анисимов В. Н. Мелатонин усиливает противоопухолевый эффект доксорубицина на модели перевиваемой опухоли эрлиха у самок мышей SHR // Материалы Петербургского онкологического форума Белые Ночи.– СПб, 2015.– С. 371. Osipov M. A., Popovich I. G., Tyndyk M. L., Panchenko A. V., Zabezhinski M. A., Semiglazova T. U., Anisimov V. N. Melatonin enhance antitumor effect of doxorubicin on the model of transplantable Ehrlich tumor in female SHR mice. // Materials of Saint-Petersburg Oncologic conference White nights.– 2015.– P.– 371.Осипов М. А., Попович И. Г., Тындык М. Л., Панченко П. А., Забежинский М. А., Семиглазова Т. Ю., Анисимов В. Н. Мелатонин усиливает противоопухолевый эффект доксорубицина на модели перевиваемой опухоли эрлиха у самок мышей SHR // Материалы Петербургского онкологического форума Белые Ночи.– СПб, 2015.– С. 371. Osipov M. A., Popovich I. G., Tyndyk M. L., Panchenko A. V., Zabezhinski M. A., Semiglazova T. U., Anisimov V. N. Melatonin enhance antitumor effect of doxorubicin on the model of transplantable Ehrlich tumor in female SHR mice. // Materials of Saint-Petersburg Oncologic conference White nights.– 2015.– P.– 371.Kidd P. Th1/th2 balance: The hypothesis, its limitations, and implications for health and disease//Altern Med Rev.–2003.– V.8-I.3-P.223–246.Kidd P. Th1/th2 balance: The hypothesis, its limitations, and implications for health and disease//Altern Med Rev.–2003.– V.8-I.3-P.223–246.Miller S. C., Pandi-Perumal S.R., Esquifino A. I. et al. The role of melatonin in immuno-enhancement: Potential application in cancer//Int J Exp Pathol.–2006.– V.87- I.2-P.81–87.Miller S. C., Pandi-Perumal S.R., Esquifino A. I. et al. The role of melatonin in immuno-enhancement: Potential application in cancer//Int J Exp Pathol.–2006.– V.87- I.2-P.81–87.Jardim-Perassi B., Ali S. Arbab, Ferreira L. et al. Effect of Melatonin on Tumor Growth and Angiogenesis in Xenograft Model of Breast Cancer // PLoS One. 2014; 9(1): e85311.Jardim-Perassi B., Ali S. Arbab, Ferreira L. et al. Effect of Melatonin on Tumor Growth and Angiogenesis in Xenograft Model of Breast Cancer // PLoS One. 2014; 9(1): e85311.Paroni R., Terraneo L., Bonomini F. Antitumor activity of melatonin in a mouse model of human prostate cancer: relationship with hypoxia signaling // J. Pineal Res.– 2014.–57.– Vol.57.– P. 43–52.Paroni R., Terraneo L., Bonomini F. Antitumor activity of melatonin in a mouse model of human prostate cancer: relationship with hypoxia signaling // J. Pineal Res.– 2014.–57.– Vol.57.– P. 43–52.Wang J., Xiao X., Zhang Y. et al. Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells // J. Pineal Res.– 2012.– Vol.53(1).– P. 77–90.Wang J., Xiao X., Zhang Y. et al. Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells // J. Pineal Res.– 2012.– Vol.53(1).– P. 77–90.Chuffa L., Alves M., Martinez M. et al. Apoptosis is triggered by melatonin in an in vivo model of ovarian carcinoma // Endocr. Relat. Cancer. – 2015. Nov 10. pii: ERC-15–0463.Chuffa L., Alves M., Martinez M. et al. Apoptosis is triggered by melatonin in an in vivo model of ovarian carcinoma // Endocr. Relat. Cancer. – 2015. Nov 10. pii: ERC-15–0463.Xi S. C., Siu S. W., Fong S. W., Shiu S. Y. Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression // Prostate –2001.– Vol.46(1).– P. 52–61.Xi S. C., Siu S. W., Fong S. W., Shiu S. Y. Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression // Prostate –2001.– Vol.46(1).– P. 52–61.Leon Blanco M., Guerrero J., Reiter R. et al. Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro // J. Pineal Res.– 2003.– Vol.35.– P. 204–11.Leon Blanco M., Guerrero J., Reiter R. et al. Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro // J. Pineal Res.– 2003.– Vol.35.– P. 204–11.Anisimov V. N., Popovich I. G., Zabezhinski M. A. et al. Melatonin as antioxidant, geroprotector and anticarcinogen// Biochim Biophys Acta.–2006.– V.1757-I.5–6-P.573–589.Anisimov V. N., Popovich I. G., Zabezhinski M. A. et al. Melatonin as antioxidant, geroprotector and anticarcinogen// Biochim Biophys Acta.–2006.– V.1757-I.5–6-P.573–589.Rodin A., Overall J. Statistical relationships of weight of the human pineal gland to age and malignancy // Cancer – 1967.– Vol.20.– P. 1203–1214.Rodin A., Overall J. Statistical relationships of weight of the human pineal gland to age and malignancy // Cancer – 1967.– Vol.20.– P. 1203–1214.Tapp E., Blumfield M. The weight of the pineal gland in malignancy // Br. J. Cancer – 1970.– Vol. 24.– P. 67–70.Tapp E., Blumfield M. The weight of the pineal gland in malignancy // Br. J. Cancer – 1970.– Vol. 24.– P. 67–70.Hajdu S., Porro R., Lieberman P., Foote F. Degeneration of the pineal gland in patients with cancer // Cancer – 1972.– Vol.29.– P. 706–709.Hajdu S., Porro R., Lieberman P., Foote F. Degeneration of the pineal gland in patients with cancer // Cancer – 1972.– Vol.29.– P. 706–709.Tapp E. The human pineal gland in malignancy // J. Neural Transm.– 1980.– Vol.48.– P. 119–129.Tapp E. The human pineal gland in malignancy // J. Neural Transm.– 1980.– Vol.48.– P. 119–129.Drexler J., Meaney T., McCormack L. The calcified pineal body and carcinoma // Clew. Clin. Q.– 1957.– Vol.24.– P. 242–247.Drexler J., Meaney T., McCormack L. The calcified pineal body and carcinoma // Clew. Clin. Q.– 1957.– Vol.24.– P. 242–247.Kutcherenko B. On the changes in cases of malignant neoformations // Probl. Endokrinol. (Mosk).– 1941.– Vol.1.– Vol.131–135.Kutcherenko B. On the changes in cases of malignant neoformations // Probl. Endokrinol. (Mosk).– 1941.– Vol.1.– Vol.131–135.Райхлин Н., Кветной И., Тюрин Е. Мелатонин в сыворотке крови онкологических пациентов // Клин. Мед.– 1980.– № 58.– С. 77–79. Reichlin N. Kvetnoy I. Tyurin E. Melatonin in serum of cancer patients // Clin. Med.– 1980.– Vol.58.– P. 77–79.Райхлин Н., Кветной И., Тюрин Е. Мелатонин в сыворотке крови онкологических пациентов // Клин. Мед.– 1980.– № 58.– С. 77–79. Reichlin N. Kvetnoy I. Tyurin E. Melatonin in serum of cancer patients // Clin. Med.– 1980.– Vol.58.– P. 77–79.Bartsch C., Bartsch H., Jain A. et al. Urinary melatonin levels in human breast cancer patients // J. Neural Transm.– 1981.– Vol.52.– P. 281–294.Bartsch C., Bartsch H., Jain A. et al. Urinary melatonin levels in human breast cancer patients // J. Neural Transm.– 1981.– Vol.52.– P. 281–294.Tamarkin L., Danforth D., Lichter A. et al. Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer // Science.– 1982.– Vol.216.– P. 1003–1005.Tamarkin L., Danforth D., Lichter A. et al. Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer // Science.– 1982.– Vol.216.– P. 1003–1005.Lissoni P., Bastone A., Sala R. et al. The clinical significance of melatonin serum determination in oncological patients and its correlations with GH and PRL blood levels // Eur. J. Cancer Clin. Oncol.– 1987.– Vol.23(7).– P. 949–57.Lissoni P., Bastone A., Sala R. et al. The clinical significance of melatonin serum determination in oncological patients and its correlations with GH and PRL blood levels // Eur. J. Cancer Clin. Oncol.– 1987.– Vol.23(7).– P. 949–57.Кветной И., Левин И. Суточная экскреция мелатонина у больных раком желудка и толстой кишки // Вопр. Онкол.– 1997.– № 33.– С. 23–32. Kvetnoy I., Levin I., The daily excretion of melatonin in patients with gastric cancer and colon cancer // Probl. In Oncol.– 1997.– Vol.33.– P. 23–32.Кветной И., Левин И. Суточная экскреция мелатонина у больных раком желудка и толстой кишки // Вопр. Онкол.– 1997.– № 33.– С. 23–32. Kvetnoy I., Levin I., The daily excretion of melatonin in patients with gastric cancer and colon cancer // Probl. In Oncol.– 1997.– Vol.33.– P. 23–32.Bartsch C., Bartsch H., Fuchs U. et al. Stage-dependent depression of melatonin in patients with primary breast cancer: Correlation with prolactin, thyroid stimulating hormone and steroid receptors // Cancer – 1989.– Vol. 64.– P. 426–433.Bartsch C., Bartsch H., Fuchs U. et al. Stage-dependent depression of melatonin in patients with primary breast cancer: Correlation with prolactin, thyroid stimulating hormone and steroid receptors // Cancer – 1989.– Vol. 64.– P. 426–433.Bartsch S., Bartsch H., Bellmann O. et al. Depression of Serum Melatonin in Patients With Primary Breast Cancer Is Not Due to an Increased Peripheral Metabolism // Cancer –1991.– Vol.67.– P. 1681–1684.Bartsch S., Bartsch H., Bellmann O. et al. Depression of Serum Melatonin in Patients With Primary Breast Cancer Is Not Due to an Increased Peripheral Metabolism // Cancer –1991.– Vol.67.– P. 1681–1684.Lissoni P., Barni S., Ardizzoia A. Randomized study with the pineal hormone melatonin versus supportive care alone in advanced non small cell lung cancer resistant to a first-line chemotherapy containing cisplatin // Oncology.– 1992.– Vol.49(5).– P. 336–9.Lissoni P., Barni S., Ardizzoia A. Randomized study with the pineal hormone melatonin versus supportive care alone in advanced non small cell lung cancer resistant to a first-line chemotherapy containing cisplatin // Oncology.– 1992.– Vol.49(5).– P. 336–9.Lissoni P., Barni S., Ardizzoia A. A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms // Cancer.– 1994.– Vol.73(3).– P. 699–701.Lissoni P., Barni S., Ardizzoia A. A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms // Cancer.– 1994.– Vol.73(3).– P. 699–701.Lissoni P. Is there a role for melatonin in supportive care? // Support. Care Cancer – 2002.– Vol.10(2).– P. 110–6.Lissoni P. Is there a role for melatonin in supportive care? // Support. Care Cancer – 2002.– Vol.10(2).– P. 110–6.Lissoni P., Brivio F., Fumagalli L. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors // Anticancer Res.– 2008.– Vol.28(2B).– P. 1377–81.Lissoni P., Brivio F., Fumagalli L. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors // Anticancer Res.– 2008.– Vol.28(2B).– P. 1377–81.Ермаченков М. Н. Влияние мелатонина на течение рака желудка и толстой кишки // автореф. дисс. кандидата мед. наук, Санкт-Петербург.– 2013.– 22 с. Ermachenkov M. N. The influence of melatonin on course gastric and colon cancer // PhD Thesis, Saint – Petersburg.– 2013.– 22p.Ермаченков М. Н. Влияние мелатонина на течение рака желудка и толстой кишки // автореф. дисс. кандидата мед. наук, Санкт-Петербург.– 2013.– 22 с. Ermachenkov M. N. The influence of melatonin on course gastric and colon cancer // PhD Thesis, Saint – Petersburg.– 2013.– 22p.Lissoni P. et al. Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone // Br. J Cancer.– 1995.– Vol. 71(4).– P. 854–856.Lissoni P. et al. Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone // Br. J Cancer.– 1995.– Vol. 71(4).– P. 854–856.Lissoni P., Barni S. A randomized study of tamoxifen plus melatonin in estrogen receptor – negative heavily pretreated metastatic breast cancer patients // Oncol. Rep.– 1995.– Vol.2.– P. 871–873.Lissoni P., Barni S. A randomized study of tamoxifen plus melatonin in estrogen receptor – negative heavily pretreated metastatic breast cancer patients // Oncol. Rep.– 1995.– Vol.2.– P. 871–873.Lissoni P., Paolorossi F., Ardizzoia A. et al. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state // J. Pineal Res.– 1997.– Vol. 23.– Р.15–19.Lissoni P., Paolorossi F., Ardizzoia A. et al. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state // J. Pineal Res.– 1997.– Vol. 23.– Р.15–19.Lissoni P., Chilelli M., Villa S. et al. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial // J. Pineal. Res.– 2003.– Vol. 35.– Р. 12–15.Lissoni P., Chilelli M., Villa S. et al. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial // J. Pineal. Res.– 2003.– Vol. 35.– Р. 12–15.Lissoni P., Barni S., Mandal M. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status // Eur. J. Cancer.– 1999.– Vol.35(12).– P. 1688–92.Lissoni P., Barni S., Mandal M. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status // Eur. J. Cancer.– 1999.– Vol.35(12).– P. 1688–92.Yan J., Shen F., Wang K., Wu M. Patients with advanced primary hepatocellular carcinoma treated by melatonin and transcatheter arterial chemoembolization: a prospective study // Hepatobiliary Pancreat. Dis. Int.– 2002.– Vol.1(2).– P. 183–6.Yan J., Shen F., Wang K., Wu M. Patients with advanced primary hepatocellular carcinoma treated by melatonin and transcatheter arterial chemoembolization: a prospective study // Hepatobiliary Pancreat. Dis. Int.– 2002.– Vol.1(2).– P. 183–6.Cerea G., Vaghi M., Ardizzoia A. et al. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low – dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5 – fluorouracil – containing combanations // Anticancer res.– 2003.– Vol. 23(2c).– P. 1951–1954.Cerea G., Vaghi M., Ardizzoia A. et al. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low – dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5 – fluorouracil – containing combanations // Anticancer res.– 2003.– Vol. 23(2c).– P. 1951–1954.Lissoni P. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms // Pathol Biol (Paris) – 2007.– Vol.55 (3–4).– P. 201–4.Lissoni P. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms // Pathol Biol (Paris) – 2007.– Vol.55 (3–4).– P. 201–4.Новик А. В., Проценко С. А., Балдуева И. А., Анисимов В. Н., Берштейн Л. М., Ткаченко Е. В., Семиглазова Т. Ю. Рандомизированное исследование II фазы по оценке применения дакарбазина в сочетании с мелатонином или метформином по сравнению с монотерапией дакарбазином в качестве 1 линии терапии диссеминированной меланомы кожи: первый промежуточный анализ результатов // Злокачественные опухоли.– 2015.– № 4(s2).– С. 267. Novik A. V., Procenko S. A., Baldueva I. A., Anisimov V. N., Berstain L. M., Tkachenko E. V., Semiglazova T. U. Randomized Phase II study evaluating the use of dacarbazine in combination with melatonin or metformin compared with monotherapy dacarbazine as a 1-line treatment of disseminated melanoma: first interim analysis of results // J. Malignant tumors.– 2015.– Vol.4(s2).– P. 267.Новик А. В., Проценко С. А., Балдуева И. А., Анисимов В. Н., Берштейн Л. М., Ткаченко Е. В., Семиглазова Т. Ю. Рандомизированное исследование II фазы по оценке применения дакарбазина в сочетании с мелатонином или метформином по сравнению с монотерапией дакарбазином в качестве 1 линии терапии диссеминированной меланомы кожи: первый промежуточный анализ результатов // Злокачественные опухоли.– 2015.– № 4(s2).– С. 267. Novik A. V., Procenko S. A., Baldueva I. A., Anisimov V. N., Berstain L. M., Tkachenko E. V., Semiglazova T. U. Randomized Phase II study evaluating the use of dacarbazine in combination with melatonin or metformin compared with monotherapy dacarbazine as a 1-line treatment of disseminated melanoma: first interim analysis of results // J. Malignant tumors.– 2015.– Vol.4(s2).– P. 267.Lissoni P., Brivio F., Barni S. Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension // Anticancer Res.–1990.– Vol.10(6).– P. 1759–61.Lissoni P., Brivio F., Barni S. Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension // Anticancer Res.–1990.– Vol.10(6).– P. 1759–61.Lissoni P., Barni S., Tancini G. et al. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma // Br. J. Cancer.– 1994.– Vol.69(1).– P. 196–9.Lissoni P., Barni S., Tancini G. et al. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma // Br. J. Cancer.– 1994.– Vol.69(1).– P. 196–9.Brackowski R., Zubelewicz B., Romanowski W. Preliminary study on modulation of the biological effects of tumor necrosis factor-alpha in advanced cancer patients by the pineal hormone melatonin // J. Biol. Regul. Homeost. Agents.– 1994.– Vol.8(3).– P. 77–80.Brackowski R., Zubelewicz B., Romanowski W. Preliminary study on modulation of the biological effects of tumor necrosis factor-alpha in advanced cancer patients by the pineal hormone melatonin // J. Biol. Regul. Homeost. Agents.– 1994.– Vol.8(3).– P. 77–80.Lissoni P., Pittalis S., Ardizzoia A. Prevention of cytokineinduced hypotension in cancer patients by the pineal hormone melatonin // Support Care Cancer.– 1996.– Vol.(4).– P. 313–6.Lissoni P., Pittalis S., Ardizzoia A. Prevention of cytokineinduced hypotension in cancer patients by the pineal hormone melatonin // Support Care Cancer.– 1996.– Vol.(4).– P. 313–6.Lissoni P., Mandal M., Brivio F. et al. Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin // Eur. Urol.– 2000.– Vol.38(1).–P. 115–8.Lissoni P., Mandal M., Brivio F. et al. Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin // Eur. Urol.– 2000.– Vol.38(1).–P. 115–8.Wang Y., Jin B., Ai F. et al. The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials // Cancer Chemother. Pharmacol.– 2012.– Vol. 69(5).– P. 1213–1220.Wang Y., Jin B., Ai F. et al. The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials // Cancer Chemother. Pharmacol.– 2012.– Vol. 69(5).– P. 1213–1220.Seely D., Ping Wu., Heidy F. et al. Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review an meta-analysis of randomized trials // Integr. Cancer Ther.– 2012.– Vol.11(4).– P. 293–303.Seely D., Ping Wu., Heidy F. et al. Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review an meta-analysis of randomized trials // Integr. Cancer Ther.– 2012.– Vol.11(4).– P. 293–303.

The authors declare that there are no conflicts of interest present.